Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 17 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital Management: As of 11 January 2024, Perpetual Limited (the parent company of J O Hambro Capital Management) holds nominally 3,128,162 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 5.004% of the total share capital and total voting rights in Zealand Pharma A/S.

公司公告–第4/2024号新西兰制药公司主要股东公告：J O Hambro Capital Management Copenhagen，Denmark，2024年1月17日–Zealand Pharma A/S（“Zealand”）（纳斯达克：ZEAL）（CVR-No.20 04 50 78），一家总部位于哥本哈根的生物技术公司，专注于创新肽基药物的发现和开发，今天宣布于2024年1月17日收到J O Hambro Capital Management根据《丹麦资本市场法》第38节发出的通知：截至2024年1月11日，永续有限公司（J O Hambro Capital Management的母公司）名义上持有新西兰制药公司3128162股（每股有一票表决权），相当于新西兰制药公司总股本和总投票权的5.004%。

Please see further details in the attached notification form. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development.

请参阅随附的通知表格中的更多详细信息。关于Zealand Pharma A/S Zealand Pharma A/S（纳斯达克：ZEAL）（“Zealand”）是一家专注于发现和开发肽类药物的生物技术公司。新西兰发明的10多种候选药物已进入临床开发阶段，其中2种已上市，3种处于后期开发阶段。

The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

该公司与多家蓝筹股制药公司建立了发展伙伴关系，并为其上市产品建立了商业伙伴关系。新西兰成立于1998年，总部位于丹麦哥本哈根，在美国拥有一支团队。有关新西兰商业和活动的更多信息，请访问http://www.zealandpharma.com.

Contact: Adam Lange (Investors)Investor Relations OfficerZealand Pharmaalange@zealandpharma.com Anna Krassowska (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand Pharmaakrassowska@zealandpharma.com .

联系人：Adam Lange（投资者）投资者关系办公室新西兰Pharmaalange@zealandpharma.comAnna Krassowska（投资者与媒体）投资者关系与企业传播副总裁新西兰Pharmaakrassowska@zealandpharma.com。

Attachment

附件

Disclosure Form - Perpetual Limited (J O Hambro Capital Management)

披露表-永续有限公司（J O Hambro Capital Management）